Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscle tone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Muscle tone. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-005010-40 Sponsor Protocol Number: 30082007 Start Date*: 2008-03-13
    Sponsor Name:Univ.-Prof. Dr. Volker Wenzel
    Full Title: Arginin Vasopressin im fortgeschrittenen vasodilatorischen Schock: Ein Dosisvergleich 2 vs. 4 IU/h
    Medical condition: 5. Einschlusskriterien 5.1. Patienten mit vasodilatorischem Schock aufgrund: a) Sepsis [Definitionen gemäss den Empfehlungen der ACCP/SCCM (12)] b) SIRS [Definitionen gemäss den Empfehlungen der ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021118 Hypotonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017723-26 Sponsor Protocol Number: Y5552120142 Start Date*: 2011-04-28
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport® intramuscular injection in the treatment of lower l...
    Medical condition: Leg Spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10024132 Leg spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) IT (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003647-29 Sponsor Protocol Number: SN-SPAS-202 Start Date*: 2020-03-23
    Sponsor Name:Solstice Neurosciences a wholly-owned subsidiary of US WorldMeds, LLC
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Followed by an Open-La...
    Medical condition: Lower Limb Spasticity
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005553-24 Sponsor Protocol Number: SN-SPAS-201 Start Date*: 2021-07-07
    Sponsor Name:Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
    Full Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-La...
    Medical condition: Upper Limb Spasticity
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000062-38 Sponsor Protocol Number: 191622-101 Start Date*: 2013-07-08
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® Treatment in Pediatric Upper Limb Spasticity: Double-blind Study
    Medical condition: Upper Limb Spasticity.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    15.1 10029205 - Nervous system disorders 10048970 Arm spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019069-28 Sponsor Protocol Number: Y-52-52120-145 Start Date*: 2011-06-07
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of upper limb...
    Medical condition: Arm Spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048970 Arm spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) PL (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-001031-63 Sponsor Protocol Number: AV650-018 Start Date*: 2007-09-20
    Sponsor Name:Avigen Inc
    Full Title: AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects...
    Medical condition: Spasticity associated with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028335 Muscle spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003271-18 Sponsor Protocol Number: GWSP20105 Start Date*: 2021-06-07
    Sponsor Name:GW Pharma Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
    Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002164-41 Sponsor Protocol Number: END-GH-2017 Start Date*: 2017-07-03
    Sponsor Name:Fundació Parc Taulí
    Full Title: Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by functional magnetic resonance imaging (fMRI) and its relation to muscle strenght and body composition.
    Medical condition: Patients with Prader-Willi Syndrome (SPW) with Growth hormone deficit.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000043-27 Sponsor Protocol Number: 191622-105 Start Date*: Information not available in EudraCT
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study
    Medical condition: Upper limb spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    14.1 10029205 - Nervous system disorders 10048970 Arm spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003117-25 Sponsor Protocol Number: V3.0 Start Date*: 2018-05-17
    Sponsor Name:Medical University of Vienna
    Full Title: Longitudinal chemodenervation effects of botulinum toxin A after intramuscular application and the impact of physical activity
    Medical condition: Spastic hemiparesis with involvement of the M. biceps brachii
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002625-29 Sponsor Protocol Number: GWSP19066 Start Date*: 2020-01-14
    Sponsor Name:GW Pharma Limited
    Full Title: A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis
    Medical condition: Symptomatic treatment of spasticity in patients with multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-002315-98 Sponsor Protocol Number: MedicalcannabisMSSCI2018 Start Date*: 2018-12-06
    Sponsor Name:Aarhus Universitetshospital
    Full Title: The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial
    Medical condition: Central neuropathic pain and spasticity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.0 10029205 - Nervous system disorders 10077975 Central neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003951-11 Sponsor Protocol Number: MRZ60201-0410 Start Date*: 2006-01-25
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, double-blind, placebo-controlled, randomized, multi-center trial with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke sp...
    Medical condition: Post-stroke spasticity of the upper limb
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028335 Muscle spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-001034-10 Sponsor Protocol Number: SativexStroke Start Date*: 2016-12-07
    Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST
    Full Title: Neurophysiological assessment of the effect of Sativex (THC/CBD oromucosal spray) as add-on to treat spasticity following stroke
    Medical condition: Spasticity following stroke
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003036-30 Sponsor Protocol Number: MRZ 60201-0607/1 Start Date*: 2007-03-08
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Ensaio clínico prospectivo, randomizado, de observador cego, com grupos paralelos e multicêntrico, para avaliar a eficácia e a segurança de duas diluições diferentes de NT 201 em pacientes com espa...
    Medical condition: Chronic upper limb spasticity caused by diverse etiologies
    Disease: Version SOC Term Classification Code Term Level
    9.0 10028335 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004934-26 Sponsor Protocol Number: N/A Start Date*: 2008-11-26
    Sponsor Name:UMCG
    Full Title: Pharmacokinetics and –dynamics of intrathecal baclofen therapy in patients with spasticity
    Medical condition: Spasticity of varying origin (i.e. MS, spinal cord injury), which doesn't respond on treatment with oral medication
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    9.1 10024132 Leg spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000073-29 Sponsor Protocol Number: MRZ 60201-0528/1 Start Date*: 2006-07-10
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomised, double-blind, placebo-controlled multicentre pilot trial to investigate the impact of an early use of NT 201 in patients with an acute cerebrovascular event on the developm...
    Medical condition: Patients with acute cerebrovascular event showing signs of beginning upper limb spasticity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10041416 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000985-36 Sponsor Protocol Number: EMCAM-2011-001 Start Date*: 2013-02-22
    Sponsor Name:JOSE MANUEL GARCIA DOMINGUEZ
    Full Title: Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as "responders" and "not responders" under t...
    Medical condition: Spasticity due to multiple sclerosis identified as "responders" and "not responders" under treatment with Sativex
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003771-18 Sponsor Protocol Number: GWSP08258 Start Date*: 2013-08-06
    Sponsor Name:GW Pharma Ltd.
    Full Title: The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic...
    Medical condition: Spasticity due to cerebral palsy (CP) or traumatic central nervous system injury.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:41:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA